Adrenohepatic fusion: Adhesion or invasion in primary virilizant giant adrenal carcinoma? Implications for surgical resection. Two case report and review of the literature  by Alastrué Vidal, Antonio et al.
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INTRODUCTION:  Adrenohepatic  fusion  means  union  between  the  adrenal  gland  and  the  liver, intermin-
gling  its parenchymas.  It is  not  possible  to  identify  this  condition  by  image  tests.  Its  presence  implies
radical  and  multidisciplinar  approach.
PRESENTATION  OF CASES:  We  report  two  female  cases  of  45  and  50 years  old  with  clinical  virilization  and
palpable  mass  on  the  abdominal  right  upper  quadrant  corresponding  to adrenocortical  carcinoma  with
hepatic  fusion.  The  contrast-enhanced  tomography  showed  an  indistinguishable  mass  involving  the  liver
and the  right  adrenal  gland.  In  the ﬁrst  case,  the  patient  had  a two-time  operation,  the former  removing
only  the  adrenal  carcinoma,  and  the  second  performing  a radical  surgery  after  an  early  relapse.  In the
second  case,  a radical  right  en  bloc  adrenohepatectomy  was  performed.  Both  cases  were  pathologically
reported  as liver-inﬁltrating  adrenal  carcinoma.  Only  in  the second  case  the  surgery  was  radical  effective
as ﬁrst intention  to treat,  with  3 years  of disease-free  survival.
DISCUSSION:  ACC  is  a rare  entity  with  poor  prognosis.  The  major  indicators  of  malignancy  are  tumour
diameter  over  6 cm,  local  invasion  or metastasis,  secretion  of corticosteroids,  virilization  and  hyper-
tension  and  hypokalaemia.  The  parenchymal  fusion  of  the  adrenal  cortical  layer can  be  misdiagnosed
as  hepatocellular  carcinoma  with  adhesion  with  the  Glisson  capsule.  AHF  in such  cases  may  be  mis-
interpreted  during  surgery,  what  may  impair  its  resectability,  and  therefore  the  survival.  The  surgical
treatment  must  be  performed  en  bloc,  often  using  liver  vascular  control.  Postoperative  treatment  must
be offered  immediately  after surgery.
CONCLUSION:  We  report  two  consecutive  rare cases  of adrenohepatic  fusion  in  giant  right  adrenocortical
carcinoma,  not  detectable  by  imaging,  what  has  important  implications  for  the  surgical  decision-making.
As  radical  surgery  is the  best  choice  to  offer  a curative  treatment,  it  has  to be  performed  by  a  multidis-
ciplinary  well-assembled  team,  counting  with  endocrine  and liver  surgeons,  and  transplant  surgeons  in
case of vena  cava  involvement,  in order  to maximize  the  disease-free  survival.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
access  article  under  the CC
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1. IntroductionAdrenohepatic fusion (AHF) means partial or complete lack
of capsular elements between the adrenal gland and the liver,
allowing parenchymatous intermingling [1]. In contrast, adhesion
(E. Barluenga Torres), jfernandezllamazares.germanstrias@gencat.cat
(J. Fernández-Llamazares Rodríguez).
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mplies an intact connective tissue septum layer. There is no pre-
ious reports of parenchymal fusion in functional giant adrenal
arcinomas, and its clinical signiﬁcance has been rarely described.
s it is not possible to identify this condition by image tests, its
resence implies radical and multidisciplinar approach to achieve
adical excision. Hereby we present a two-case report of adreno-
ortical carcinoma (ACC) with AHF, presented as malignant hepatic
umour by imaging.
. Presentation of cases
Two previously healthy caucasian women of 45 and 50 years
ld with history of 9 and 6 months of clinical virilization and pal-
able mass on the right abdominal upper quadrant were submitted
onsecutively to our hospital from primary care. Both patients
resented with clinical signs of virilization (centripetal obesity, hir-
utism, facial acne, hypertension and oligo/amenorrhea), although
he second case presented with mild hirsutism and oligomenor-
hea. Both were studied by ultrasonography (US), computerized
omography (CT) and nuclear magnetic resonance (MRI), observ-
ng an indistinguishable mass involving the liver and the right
drenal gland (Fig. 1). Hormone laboratories dehydroepiandros-
erone (DHEA) and its sulphate metabolite (DHEAS), cortisol and
estosterone were signiﬁcative for functional suprarenal tumour.
he two cases are reported in line with the CARE criteria.
.1. Radiologic features
In the ﬁrst case (Fig. 2), a large solid mass of 16.2 × 13.2 × 12.7 cm
n craniocaudal, laterolateral, and anteroposterior (CC, LL, AP)
iameters was seen on a non-contrast CT, occupying the main part
f the right liver lobe (RLL) and pulling down the right kidney, with
eterogeneous intravenous (IV) contrast enhancement. The infe-
ior vena cava (IVC) was stenosed, from the left renal vein to the
ain hepatic veins (MHV). No thrombus was seen within the portal
ein (PV). In this case no ulterior radiological exam was considered
revious to surgery.
In the second case (Fig. 3), a large hypo-dense mass of
0.3 × 17.5 × 15.6 cm (CC, LL, AP) was seen at on a non-contrast CT,
ffecting the RLL, but also caudate lobe and segment 4b, with an
nnular-peripheral arterial hyper-density after contrast enhanced
T, as well as intratumoural hypertrophic vessels. The splenoportal
xis were permeable but pulled onto front. The retro-hepatic IVC
as extremely stenosed. When looked at on a contrast-enhanced
RI  (Multihance) imaging, there was a large mass of non-fatty solid
ig. 1. CT scan comparing the two initial image studies. Both patients showed virilizatio
ase.  2: Second case.PEN  ACCESS
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density with central foci of haemorragic necrosis, and peripheral
neovessels. Iliocavography showed an extrinsic IVC compression
from the back, with azygos, hemiazygos, lumbar veins and par-
avertebral vein plexus dilated, which are pathognomonic signs of
adrenal mass, but cannot discard a large hepatic tumour with extra-
capsular spreading. The transesophageal echocardiogram (TEE)
ruled out atrial cardiac tumoural thrombus before US-guided trans-
hepatic core-biopsy was performed, being positive for adrenal
carcinoma.
2.2.1. Surgical technique proceedings
Both cases were operated in one month interlude. The former
patient had a medial laparotomy extended to 9th costal arc. As ﬁrst
step, proximal and distal IVC and renal veins control was  obtained
with vessel loops. A right nephrectomy was required due to the crit-
ical proximity with the lesion. A blunt dissection along the cleavage
plain identiﬁed a large part of the lesion inﬁltrating the RLL, which
was enucleated in a second time (Fig. 2).
The latter case was  preceded by the placement of a secu-
rity balloon catheter in the cardiac atrium, via retrohepatic IVC,
and selective femoral transarterial right hepatic embolization with
150–300 m microspheres. The patient had a Chevron bilateral
subcostal laparotomy with xiphoid extension. After liver mobi-
lization and total vascular control, piggy-back manoeuvre was
performed, avoiding venovenous by-pass (VVB). As the cleavage
plane between the mass and the liver was inexistent, a right
extended hepatectomy was performed (Fig. 4).
Both patients received preoperative prophylaxis and cortisol
adrenal preconditioning, and 2 unit blood transfusion intraopera-
tively. Pain was  successfully managed through a patient-controlled
analgesia pump. The postoperative course was uneventful and the
patients were discharged after 12 and 9 days respectively.
2.2.2. Anatomopathological ﬁndings
Both specimens were solid and ﬁrm. The cut surface appeared
yellowish grey (Fig. 5), with haemorragic areas. The hepatic cap-
sule included the adrenal gland in both cases. Microscopically, the
tumour consisted of nests or trabeculae interrupted by a thin sinu-
soidal capillary web. The tumoural cells were round polygonal and
had clear microvesicular cytoplasm with ovoid nuclei. More com-
pact areas consisting of smaller cells with eosinophilic granular
cytoplasm were also found. Cellular atypia were infrequent and
no mitotic ﬁgures were identiﬁed. A thin ﬁbrous capsule separated
the adrenal gland and the liver over the most part of their respec-
tive surfaces. However, multiple foci of inﬁltration were identiﬁed
n symptoms and right lobe liver mass. Diagnosis was adrenal carcinoma. 1: First
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Fig. 2. First case. Large adrenal mass compressing right liver lobe and displacing vena cava and right renal vein. No thrombus shown. Right: on portal equilibrium phase,
large  areas of low attenuation coefﬁcient, attributed to tumoral necrosis, surrounded by a hyperattenuated capsule.
Fig. 3. Second case. Large mass displacing but also merging with the liver. It can be seen I
the  hepatic veins, as also contacts with the right atrium, without invading IVC.
Fig. 4. Second case. Macroscopic picture of the adrenohepatic resection en bloc
specimen.VC and right renal vein stenosis. The mass pulls out the diaphragm and compresses
where the parenchyma of the two organs had direct contact with
each other. This ﬁnding was consistent with AHF, but including
also cellular atypia and neoplastic inﬁltration, so the ﬁnal anato-
mopathological diagnosis was  inﬁltrating adrenal carcinoma.
2.2.3. Follow-up
In the ﬁrst case, a one month postoperative CT demonstrated a
liquid-density collection besides the liver and showed progression
after 3 months, suggesting early neoplastic recurrence, so mitotane
treatment was started. A positron emission tomography (PET) scan
9 months after, revealed local relapse, but also ruled out distant
metastases, so a salvage right hepatectomy was performed. The
postoperative course was  uneventful. The liver specimen revealed
again neoplastic inﬁltration. After 2 years the patient died from
metastatic recurrence. In the second case, the CT scan after 6
months showed no relapse. Nevertheless, after 3 years disease-free
follow-up, the patient was  diagnosed with pulmonary metastases.
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Wig. 5. Second case. Anatomopathological macroscopical aspect of the AHF detailing
nﬁltration line (black arrow).
. Discussion
ACC is a rare entity with an estimated incidence of 1 per 1.7 mil-
ion [2], representing around 0.02% of all neoplasia. It has bimodal
ge distribution, peaking at ﬁrst and ﬁfth decade. It is more com-
on  in women [3], but its presentation as virilization is rare [4].
CC aetiology is idiopathic, and its prognosis is very poor due to
ts aggressive behavior [5]. The diagnosis is made frequently late
nd incidentally, often after vascular invasion [6]. According to
chechter [7], AHF is one sort of aberrant adrenal tissue hetero-
opia, in contrast to the adrenohepatic adhesion, and has partially
acking connective tissue septum [8].
.1. Differential diagnosis
Before an abdominal right upper quadrant mass it should
e ruled out adrenal cortical adenoma, clear cell hepatocellular
arcinoma, pheocromocitoma, paraganglioma (including multiple
ndocrine neoplasia (MEN) type 2, Von Hippel Lindau disease or
amilial paragangliomas), adrenal collision or composite tumour,
drenal rest tumour, and also adrenal metastasis. It is important
o discard pheocromocitoma and functional paraganglioma prior
o treatment, in order to receive hormonal suppression and/or be
mbolized previous to surgery [9].
Hormone labs are helpful. In women, malignant tumour is
nlikely present if serum DHEAS and urinary 17-ketosteroid (17-
S) excretion are between basal range and serum cortisol after
examethasone is below 3.3 g/dL, with sensitivity and speciﬁcity
f 100% [5]. In our two cases, normal 24-h urine vanillylmandelic
able 1
eiss criteria for malignancy.
Original Weiss criteria for malignancy, requires 3+ of these factors:
>5 mitotic ﬁgures/50HPF (40 × objective), counting 10 random ﬁelds in area of greatest
Nuclear grade III or IV based on Fuhrman criteria
Presence of atypical mitotic ﬁgures (abnormal distribution of chromosomes or excessiv
Clear or vacuolated cells comprising 25% or less of tumor
Diffuse architecture (more than 1/3 of tumor forms patternless sheets of cells; trabecul
diffuse)
Microscopic necrosis
Venous invasion (veins must have smooth muscle in wall; tumor cell clusters or sheets
thrombi covered by endothelial layer)
Sinusoidal invasion (sinusoid is endothelial lined vessel in adrenal gland with little sup
Capsular invasion (nests or cords of tumor extending into or through capsule with a strPEN  ACCESS
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acid (VMA) depicted the non-functional nature of the tumour. Per-
cutaneous preoperative biopsy must be done with extreme caution,
as it can potentially result in life-threatening crisis [9]. In the sec-
ond case, a full precaution core biopsy was taken, being positive for
carcinoma.
ACC is deﬁned as the tumour meets the Weiss classic standard
criteria [10]. The pathologic diagnosis is based on the recogni-
tion of at least three of nine morphological parameters by optic
microscopy (Table 1). The Weiss scoring system is the most widely
employed score [11]. Well-established histopathological items and
Ki-67 expression can speciﬁcally distinguish adrenocortical ade-
noma from carcinoma [12]. Immunohistochemical study of adrenal
steroidogenic factor 1 (SF-1), can help. Moreover, the major indica-
tors of malignancy are tumour diameter over 6 cm,  documented
local invasion or metastasis, secretion of more than one class
of corticosteroids, virilization and associated hypertension and/or
hypokalaemia [13].
The clinical adrenal-induced virilization can be conﬁrmed by
measuring serum testosterone, serum adrenal androgens (DHEA
and DHEAS) and 24-h 17-KS. As proposed by Ross and Aron
[14], potassium and total urinary catecholamine and metanephrine
should be evaluated to rule out pheochromocytoma specially in
patients with hypertension, so it was  done in both cases.
Plasma and urinary steroids (including DHEA and DHEAS),
androstenediol, 4-androstenedione, pregnenolone, 17-
hydroxypregnenolone and 11-deoxycortisol as well as urinary
17-ketosteroid (17-KS), 17-hydroxycorticosteroid (17-OHCS) and
the tetrahydrometabolite of 11-deoxycortisol may be elevated
because in ACC many steroid enzymes are defective. Reviewed
series [4] show that the most common steroids assayed were
24-h urinary excretion of 17-KS and 17-OHCS, but also plasma
DHEA and DHEAS. Hormonally active ACC express the insulin-
like growth factor II (ILGF-II) gene. In addition, levels of both
transforming growth factor alpha (TGF-a) and epidermal-like
growth factor (ELGF) receptor expression were markedly higher in
adrenocortical carcinomas than in benign tumours.
Despite to be a rare tumour, Honma [15] reported that AHF is
a rather not uncommon autopsy incidental ﬁnding, reaching 10%,
what way  suggest that it may  be an acquired age-related phe-
nomenon [7], although hepatocellular carcinoma can invade the
right adrenal gland with AHF [16]. The development process of AHF
has been proposed to be a differentiation failure of the interven-
ing fat tissue [7], as a defective formation of the organ capsules
from the periadrenal mesenchymal stroma during the embryonic
development [17]. The role of the intercellular communication dis-
ruption in adrenocortical adrenal tumourigenesis was introduced
by Marx et al. [18]. To our knowledge, there are many few cases of
adrenal cortical tumour with AHF described in the literature [19],
what lead us to think that the adhesion between the liver and the
adrenal gland can be an acquired condition [20].
 number of mitotic ﬁgures on 5 slides with greatest number of mitoses
e number of mitotic spindles)
ar, cord, columnar, alveolar or nesting pattern is not considered to be
 forming polypoid projections into vessel lumen or polypoid tumor
portive tissue; consider only sinusoids within tumor)
omal reaction); either incomplete or complete
 –  O
2 rnal o
3
s
r
D
n
i
H
a
7
a
o
h
l
o
h
c
g
d
e
T
t
l
b
ﬁ
d
b
l
u
I
3
c
a
t
s
d
M
t
g
t
a
b
t
c
i
w
m
D
t
s
e
t
t
[
t
a
aCASE  REPORT
8 A. Alastrué Vidal et al. / International Jou
.2. Radiologic highlights
The radiologic study must count on US and CT/MRI, what may
erve as a guide for a safe biopsy. The performance of a TEE may
ule out the possibility of atrium thrombus. As seen on Abdominal
oppler US and CT/MRI scan, malignant tumours have heteroge-
ous zones with intratumoural haemorrhage, necrosis and ﬁbrosis,
rregular margins and calciﬁcations. High density measurement of
ounsﬁeld units (>10 HU) in an unenhanced CT is indicative for
 low fat content, providing strong evidence of malignancy with
1% sensitivity and 98% speciﬁcity [21]. However, 20HU may  be
n acceptable density cut-off value for a mass <4 cm in absence
f malignancy history [22]. It is recommendable to use sulphur
exaﬂuoride surfactant-stabilized microbubbles as contrast in US
iver imaging before percutaneous ﬁne-needle aspiration cytol-
gy (FNAC) or CT/US-guided core-biopsy, in order to minimize the
aemorragic risk [23]. Open biopsy is then only required in doubtful
ases.
The attachment between the hepatic lesion and the adrenal
land could be seen by careful review of the thin-section CT
ata set with the multiplanar reformation technique (MPR). How-
ver, fat plane is not always visible on CT in thin patients.
he intrahepatic presence of the adrenal cortical layer can
hen be misdiagnosed as hepatocellular carcinoma, both radio-
ogically [16] and pathologically [24]. AHF in such cases may
e misinterpreted during the surgery, as happened in the
rst case. This is particularly important in the perioperative
ecision-making process. Notwithstanding, the resection must
e performed with negative margins (R0), what may  include
ymphadenectomy or open cava thrombectomy en bloc, often
sing liver transplant techniques to mobilize the liver off the
VC [25].
.3. Surgical highlights
The importance of the IVC control is a key factor during the surgi-
al act [26]. It is critical to perform a proper piggy-back manoeuvre,
s well as clamping the MHV  when needed [27]. Occasionally,
his type of procedures may  be technically challenging for the
urgeon, sometimes requiring veno-venous bypass (VVB) or car-
iopulmonary bypass (CPB) if the cardiac atrium is involved [27].
HV and PV must be controlled as a ﬁrst step to surgical resec-
ion [28], allowing a right hepatectomy en bloc with the adrenal
land and/or the right kidney. In the two hereby presented cases
he vascular control consisted of infrarenal vena cava vessel loop
nd Pringle manoeuvre, while in the second case a cardiac atrium
alloon-occluding catheter was used for a superior vena cava con-
rol.
Complete surgical excision is the only palliative option in most
ases [29] and provides acceptable results in survival and qual-
ty of life, but also signiﬁcant morbidity and mortality rates. IVC
all invasion and the tumour thrombus extension are major deter-
inants for the surgical approach [28], even requiring CPB and
HCA. In addition, there may  be paracaval lymph node involvement
hat may  be resected. In our two cases, the lymph node dissection
howed no IVC inﬁltration.
IVC can be stenosed or occluded by tumour thrombus with low
xtremity oedema, thus developing collateral circulation [8]. In
hese cases, IVC must be resected. Autogenous vein graft substitu-
ion might not be technically feasible for long segments [26]. PTFE
29], Dacron and Gore-Tex 18–20 mm ringed grafts are currently
he best choice [30]. Anticoagulation has not proven any beneﬁt,
lthough proposed empirically by some authors (low dose heparin
long with long-term maintenance aspirin) [30].PEN  ACCESS
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3.4. Postoperative management
The prognosis of ACC is poor if untreated with a 20% 1-year
survival. Functioning tumours have larger survivals than non-
functioning. Distant metastases may narrow 5-year survival from
50% to 0%. Only 30% of patients are diagnosed in early stages (I–II), so
70% do it in advanced stages (III–IV). 5-year survival is 60% for stage
I, 58% for stage II, 24% for stage III, and 0% for stage IV, respectively.
Relapse is estimated around 84% even after R0 surgery [31].
Adjuvant chemotherapy must be offered immediately after
surgery. Mitotane is the ﬁrst election drug, associated or not
with cytotoxic treatment [32], by cortisol metabolism 11-
beta-hidroxilase inhibition. Recently an albumin-binding matrix-
associated protein has been proposed as a mechanism to increase
the efﬁcacy of the antimicrotubular drug Paclitaxel (nab-paclitaxel)
[33]. In our study both patients received mitotane as adjuvant
treatment, but only the second had relative long-term disease-free
survival. This fact reafﬁrms the author’s notion that a radical en
bloc ﬁrst intention-to-treat surgical resection is mandatory.
Conclusions
Virilizing adrenal carcinoma is a rare entity that must be dis-
carded before a large mass in the RLL, by imaging studies (US, CT or
MRI) and hormone expression labs. To our best knowledge, there
is no ACC presented with AHF reported in the literature. Radiol-
ogists should be aware of this potential occurrence in order to
help the surgical decision-making, as the biopsy may  be crucial to
rule out the possibility of ACC prior to consider aggressive surgical
treatment.
The surgical resection must include the RHL  en bloc with the
right adrenal gland when AHF is suspected. A multidisciplinary
well-assembled team, counting with endocrine and liver surgeons,
and transplant surgeons in case of IVC involvement, what may
require venous bypass, or even IVC open exploration, should per-
form this surgical procedure.
Considering radical surgery as the best choice to offer signiﬁca-
tive disease-free survival, we strongly recommend a radical surgery
including the RHL en bloc with the right adrenal gland, as done in
the second case presented.
Thus, surgery must be performed in a radical, but also extreme
and well-planned manner.
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